Clinical guideline for 9-valent HPV vaccine: Korean society of gynecologic oncology guideline

Kyung Jin Min; Sang Hoon Kwon; Kidong Kim; Sunghoon Kim; Hyun Jung Kim; Seok Ju Seong; Yong Jung Song; Keun Ho Lee; Shin Wha Lee; Jeong Won Lee; Suk Joon Chang; Woong Ju; Young Tak Kim; Jae Kwan Lee

doi:10.3802/jgo.2019.30.e31

Clinical guideline for 9-valent HPV vaccine: Korean society of gynecologic oncology guideline

Kyung Jin Min, Sang Hoon Kwon, Kidong Kim, Sunghoon Kim, Hyun Jung Kim, Seok Ju Seong, Yong Jung Song, Keun Ho Lee, Shin Wha Lee, Jeong Won Lee, Suk Joon Chang, Woong Ju, Young Tak Kim, Jae Kwan Lee

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.

Original language	English
Article number	e31
Journal	Journal of Gynecologic Oncology
Volume	30
Issue number	2
DOIs	https://doi.org/10.3802/jgo.2019.30.e31
State	Published - Mar 2019

Bibliographical note

Publisher Copyright:
© 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.

Keywords

Female
Male
Papillomavirus vaccines
Practice guidelines

Access to Document

10.3802/jgo.2019.30.e31

Cite this

@article{14f5eea009054cd3814e8f602220f276,

title = "Clinical guideline for 9-valent HPV vaccine: Korean society of gynecologic oncology guideline",

abstract = "In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.",

keywords = "Female, Male, Papillomavirus vaccines, Practice guidelines",

author = "Min, {Kyung Jin} and Kwon, {Sang Hoon} and Kidong Kim and Sunghoon Kim and Kim, {Hyun Jung} and Seong, {Seok Ju} and Song, {Yong Jung} and Lee, {Keun Ho} and Lee, {Shin Wha} and Lee, {Jeong Won} and Chang, {Suk Joon} and Woong Ju and Kim, {Young Tak} and Lee, {Jae Kwan}",

note = "Publisher Copyright: {\textcopyright} 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.",

year = "2019",

month = mar,

doi = "10.3802/jgo.2019.30.e31",

language = "English",

volume = "30",

journal = "Journal of Gynecologic Oncology",

issn = "2005-0380",

publisher = "Korean Society of Gynecologic Oncology and Colposcopy",

number = "2",

}

TY - JOUR

T1 - Clinical guideline for 9-valent HPV vaccine

T2 - Korean society of gynecologic oncology guideline

AU - Min, Kyung Jin

AU - Kwon, Sang Hoon

AU - Kim, Kidong

AU - Kim, Sunghoon

AU - Kim, Hyun Jung

AU - Seong, Seok Ju

AU - Song, Yong Jung

AU - Lee, Keun Ho

AU - Lee, Shin Wha

AU - Lee, Jeong Won

AU - Chang, Suk Joon

AU - Ju, Woong

AU - Kim, Young Tak

AU - Lee, Jae Kwan

PY - 2019/3

Y1 - 2019/3

N2 - In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.

AB - In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.

KW - Female

KW - Male

KW - Papillomavirus vaccines

KW - Practice guidelines

UR - http://www.scopus.com/inward/record.url?scp=85062188797&partnerID=8YFLogxK

U2 - 10.3802/jgo.2019.30.e31

DO - 10.3802/jgo.2019.30.e31

M3 - Article

C2 - 30740959

AN - SCOPUS:85062188797

SN - 2005-0380

VL - 30

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

IS - 2

M1 - e31

ER -

Clinical guideline for 9-valent HPV vaccine: Korean society of gynecologic oncology guideline

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this